Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Omalizumab worth it in severe persistent asthma

    This is a preview of subscription content, log in to check access.

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

    REFERENCE

    1. 1.

      Dewilde S, Turk F, Tambour M, Sandström T.The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Current Medical Research and Opinion 22: 1765-1776, No. 9, Sep 2006

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Omalizumab worth it in severe persistent asthma. Pharmacoecon. Outcomes News 515, 12 (2006). https://doi.org/10.2165/00151234-200605150-00042

    Download citation

    Keywords

    • Asthma
    • Incremental Cost Effectiveness Ratio
    • Allergic Asthma
    • Omalizumab
    • Persistent Asthma